Non-alcoholic Steatohepatitis Treatment Market Report Scope and Overview:

The Non-alcoholic Steatohepatitis Treatment Market was valued at USD 9.50 Billion in 2025 and is projected to reach USD 103.70 Billion by 2035, registering a CAGR of 27.0% from 2026 to 2035.

Non-alcoholic steatohepatitis (often called metabolic dysfunction-associated steatohepatitis), which is considered an ominous development of non-alcoholic fatty liver disease, is a condition characterized by inflammation of the liver and scarring leading to cirrhosis and sometimes hepatocellular carcinoma. The prevalence of non-alcoholic steatohepatitis is rising all over the world due to certain lifestyle problems such as obesity, a lack of physical activity, unhealthy nutrition, and other diseases accompanying NASH like obesity, nonalcoholic fatty liver disease, type 2 diabetes, hypertension, hypercholesterolemia, and metabolic syndrome. This development has occurred alongside a growing global prevalence of obesity, type 2 diabetes, metabolic syndrome, and sedentary lifestyles, with improved methods of screening, diagnosis, and increasing approvals of innovative and effective therapies continuing to drive genuinely explosive market growth.

GLP-1 receptor agonists, including semaglutide, continued gaining genuine market traction throughout 2025 following a recent FDA accelerated approval for use with NASH, reflecting proven efficacy in both resolution of steatohepatitis and improvement in fibrosis, as well as reduction in weight and positive metabolic outcomes that improve the upstream drivers of disease progression.

Market Size and Forecast

• Market Size in 2026E: USD 12.07 Billion
• Market Size by 2035: USD 103.70 Billion
• CAGR: 27.0% from 2026 to 2035
• Fastest Growing Region: Asia Pacific
• Largest Region: North America

To Get more information Non-alcoholic Steatohepatitis Treatment Market - Request Free Sample Report

Non-alcoholic Steatohepatitis Treatment Market Trends

• Public and medical awareness of NASH continues increasing globally, with health authorities and organizations including the World Health Organization running awareness campaigns about liver health.
• Detecting NASH in its early stages continues allowing timely treatment, as early testing and diagnosis become increasingly common.
• The integration of artificial intelligence and machine learning technologies continues representing a key factor driving improved diagnosis and treatment personalization.
• Growing global prevalence of obesity, type 2 diabetes, and metabolic disorders continues coupling with increasing approvals of innovative and effective therapies.
• Favorable government support for early-stage disease intervention continues driving genuine segmental growth across earlier NASH fibrosis stages.

The US Non-alcoholic Steatohepatitis Treatment Market Outlook

The US Non-alcoholic Steatohepatitis Treatment Market was valued at approximately USD 4.70 Billion in 2025 and is projected to reach approximately USD 50.13 Billion by 2035, registering a CAGR of approximately 26.7% from 2026 to 2035.

Country-wise, the non-alcoholic steatohepatitis treatment market in the United States continued dominating North America throughout the year, anchored by rising number of people with obesity and type 2 diabetes across the domestic population. These factors, frequently attributed to the consumption of foods rich in fat content and lack of physical activity, kept on increasing the likelihood of NASH, an ailment involving accumulation of fat, inflammation, and possibly, damage to the liver. The increasing consciousness and awareness levels of the public, in addition to growing diagnostics facilities, helped maintain the dominance of the country as the global market leader in terms of NASH adoption and pipelines.

Madrigal Pharmaceuticals continued expanding commercial availability of its approved NASH therapeutic throughout 2025, targeting American hepatologists and endocrinologists seeking proven treatment options capable of addressing liver fibrosis and inflammation across increasingly diagnosed early and moderate-stage NASH patient populations.

Non-alcoholic Steatohepatitis Treatment Market Segmentation Analysis

• By Drug Type, Vitamin E and Pioglitazone led the market with an estimated 36.5% to 88.31% share in 2025, while Semaglutide was the fastest-growing drug type, tracking rising GLP-1 receptor agonist adoption.
• By Disease Stage, NASH Stage F1 led the market with an estimated 32.4% to 34.75% share in 2025, while NASH Stage F0 was the fastest-growing disease stage, tracking rising early-diagnosis intervention rates.
• By Distribution Channel, Hospital Pharmacies led the market with an estimated 52.2% share in 2025, while Retail and Specialty Pharmacies was the fastest-growing distribution channel.

By Drug Type, vitamin E and pioglitazone led the non-alcoholic steatohepatitis treatment market, semaglutide grew fastest

By drug, vitamin E and pioglitazone dominated the market and accounted for up to 88.31% of global revenue, attributable to the unavailability of approved drugs in the market during much of the category's historical development. This class has been established as having efficacy in reducing liver enzymes and improving histopathology related to NASH in many patients, is inexpensive, and has been adopted first with global access, keeping this drug type the dominant category by a considerable margin over emerging pharmacological alternatives.

The current fastest-growing pharmacological class in the forecast period is semaglutide, as GLP-1 receptor agonists represent a growth area due to a recent FDA accelerated approval for use with NASH. This approval reflects proven efficacy in both resolution of steatohepatitis and improvement in fibrosis, as well as reduction in weight and positive metabolic outcomes that improve upstream drivers, keeping this drug type's growth rate climbing well ahead of the broader, historically-dominant vitamin E and pioglitazone segment.

By Disease Stage, NASH Stage F1 led the non-alcoholic steatohepatitis treatment market, NASH Stage F0 grew fastest

By disease stage, the NASH stage F1 segment dominated the market with a share of up to 34.75%. NASH stage F1 is a stage causing minimal fibrosis without septa, tissue changes that show advancing liver damage, and it remains an essential stage as NASH initiates from this stage. Patients experience symptoms at this stage, allowing for rapid diagnosis, and the latest advancements in diagnosis and effective treatment plans to prevent entering advanced NASH stages continue promoting this segment's dominant position by a considerable margin.

By disease stage, the NASH stage F0 segment is anticipated to grow with the highest CAGR in the market during the forecast period. It is the most preliminary stage of NASH, showing signs of fatty liver but no fibrosis, with segmental growth attributed to favorable government support for early-stage disease intervention, keeping this disease-stage category's growth rate climbing well ahead of the broader, still-dominant Stage F1 segment.

By Distribution Channel, hospital pharmacies led the non-alcoholic steatohepatitis treatment market, retail and specialty pharmacies grew fastest

Hospital pharmacies emerged as the leading distribution channel, accounting for 52.2% of total market revenue, thanks to better drug access and infrastructure within clinical treatment settings. That combination of established clinical distribution infrastructure and genuine treatment continuity kept hospital pharmacies the dominant distribution-channel category by a considerable margin over retail and online alternatives.

By distribution channel, the retail and specialty pharmacies segment is predicted to witness significant growth in the market over the forecast period. As increasingly diverse NASH therapeutics continue expanding beyond purely hospital-administered treatment protocols toward outpatient and self-administered options, that broadening treatment accessibility keeps this distribution-channel category's growth rate climbing well ahead of the broader, still-dominant hospital pharmacies segment.

Regional Analysis

North America Non-alcoholic Steatohepatitis Treatment Market Insights

North America dominated the global non-alcoholic steatohepatitis treatment market with a share of up to 79% in 2025, driven by rising NASH prevalence, increasing obesity rates, and proactive regulatory approvals for new therapeutics. That combination of genuine disease prevalence and expanding pharmaceutical innovation infrastructure kept the continent firmly positioned as the market's clear leader by a considerable margin over every other region tracked in this report.

The United States accounted for roughly 85.30% of regional revenue, anchored by rising numbers of people with obesity and type 2 diabetes, and a leading position in both treatment adoption and pipeline drug development. Canada added further regional demand through its own growing hepatology and endocrinology treatment infrastructure, and that combined strength kept North America the largest addressable market for NASH treatment vendors through the forecast period.

Get Customized Report as per Your Business Requirement - Enquiry Now

Europe Non-alcoholic Steatohepatitis Treatment Market Insights

Europe held a meaningful share of global revenue, supported by growing NASH awareness campaigns and expanding early-testing infrastructure across the region's major healthcare systems. Continued regulatory emphasis on liver health screening kept reinforcing steady European demand for NASH treatment options throughout the year.

Germany led demand at roughly 24.05% of European revenue, supported by its substantial healthcare infrastructure and pharmaceutical research base. The UK and France contributed substantial additional demand, and continued European investment in early NASH diagnosis should keep regional demand climbing through the forecast period.

Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Insights

Asia-Pacific is projected to host the fastest-growing market in the coming years, driven by rapidly rising obesity and type 2 diabetes prevalence alongside expanding healthcare infrastructure investment across the region's largest economies. Growing public and medical awareness of NASH continued driving regional growth well ahead of every other region tracked in this report.

China led the pack, supported by its massive population base and rapidly growing domestic prevalence of metabolic syndrome and related liver disease. India and Japan contributed meaningful additional demand, with expanding healthcare infrastructure and rising diagnosis rates continuing to reinforce Asia Pacific's position as the fastest-growing market tracked in this report.

MEA and Latin America Non-alcoholic Steatohepatitis Treatment Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding healthcare infrastructure investment, growing obesity and metabolic disorder prevalence, and rising government focus on liver health screening across both areas. As these markets continued developing modern diagnostic and treatment infrastructure, NASH treatment adoption grew correspondingly from a considerably smaller base than in more mature markets.

The UAE led Middle East and Africa demand, supported by growing healthcare infrastructure investment and rising metabolic disorder prevalence. Saudi Arabia contributed further demand through its own healthcare modernization programs. In Latin America, Brazil accounted for the largest share of regional revenue, with growing obesity and diabetes prevalence continuing to anchor regional demand for NASH treatment.

Growth Drivers: Rising Obesity Prevalence and Innovative Therapy Approvals

A key driver behind this surge is the rising number of people with obesity and type 2 diabetes. These conditions, often caused by high-fat diets and sedentary lifestyles, increase the risk of NASH, a liver disease marked by fat buildup, inflammation, and potential liver damage. Over 890 million people worldwide were identified as obese in 2022, and the diabetic population was estimated at 529 million in 2023, with 96% having type 2 diabetes.

The market is expanding rapidly, driven by rising obesity, poor diets, and lack of physical activity worldwide, coupled with the surging global prevalence of obesity, type 2 diabetes, and metabolic disorders and increasing approvals of innovative and effective therapies. That combination of genuine disease burden escalation and expanding pharmaceutical innovation is exactly what keeps demand climbing at such a rapid, sustained pace across virtually every major consuming region this market serves.

Restraints: Limited Approved Treatment Options and Diagnostic Complexity

The historical unavailability of approved drugs in the market continues posing a genuine restraint, as vitamin E and pioglitazone's dominant market position stems substantially from the lack of alternative approved therapeutics rather than pure clinical superiority. That treatment gap keeps the addressable market genuinely constrained until additional pipeline therapies achieve regulatory approval.

The genuine diagnostic complexity of accurately staging NASH disease progression continues posing a further restraint, as diagnosis requires multiple techniques including physical examination, blood tests, liver biopsy, magnetic resonance imaging, and ultrasound. That diagnostic burden keeps early-stage disease identification genuinely more resource-intensive than simpler, more routine diagnostic pathways in many healthcare systems.

Opportunities: GLP-1 Receptor Agonist Expansion and Early-Stage Intervention Development

GLP-1 receptor agonists gaining traction following recent FDA accelerated approval represent a genuinely significant opportunity, as this drug type's fastest-growing status among all segments tracked in this market reflects proven efficacy in both resolution of steatohepatitis and improvement in fibrosis. Vendors offering genuinely proven, dual-benefit metabolic and hepatic therapeutics stand to capture meaningful share as this drug class continues expanding treatment options beyond the market's historically dominant vitamin E and pioglitazone stronghold.

Favorable government support for early-stage disease intervention offers a second substantial opportunity, as this NASH Stage F0 category's fastest-growing status reflects genuine policy and clinical emphasis on identifying and treating disease before advanced fibrosis develops. Vendors that can deliver genuinely effective early-intervention therapeutics stand to capture meaningful share as diagnostic capability and screening infrastructure continue expanding globally.

Recent Developments:

• 2025: Novo Nordisk continued expanding clinical development of semaglutide for NASH indications, targeting patients seeking dual metabolic and hepatic benefit from GLP-1 receptor agonist therapy.
• 2025: Akero Therapeutics continued advancing its late-stage pipeline NASH therapeutic candidates, targeting patients with moderate to advanced liver fibrosis seeking genuinely effective disease progression management.
• 2024: Gilead Sciences continued expanding its liver disease research and development portfolio, targeting NASH patients across multiple fibrosis stages seeking proven, well-tolerated treatment options.

Non-alcoholic Steatohepatitis Treatment Market key players are:

• Novo Nordisk A/S
• Intercept Pharmaceuticals, Inc.
• Madrigal Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• Pfizer Inc.
• Boehringer Ingelheim GmbH
• Genfit S.A.
• Akero Therapeutics, Inc.
• Viking Therapeutics, Inc.
• 89bio, Inc.
• Inventiva S.A.
• Sagimet Biosciences Inc.
• Terns Pharmaceuticals, Inc.
• Galmed Pharmaceuticals Ltd.
• Zydus Lifesciences Limited
• NGM Biopharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• AstraZeneca plc
• Alfasigma S.p.A.

Non-alcoholic Steatohepatitis Treatment Market Report Scope :